The final guidance for postmarket cybersecurity management arrived after more than four dozen comments to the docket, and one change to the draft version is immediately apparent. The U.S. FDA dropped the section describing "essential clinical performance" from the guidance in the final version, a term some in industry saw as too ambiguous to be of much use. Read More
